New product: Tafinlar (dabrafenib) 50mg & 75mg hard capsules -

New product: Tafinlar (dabrafenib) 50mg & 75mg hard capsules
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers
Summary
Dabrafenib, an inhibitor of RAF kinases, is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
UKMi comment
NICE guidance on dabrafenib (and trametinib) for the treatment of BRAF V600 mutation positive, unresectable, advanced or metastatic melanoma is currently in development (expected September 2014).
Related links: NICE guidance (in development)